Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-anti-DPP6 nanobody
- Development stage
- Preclinical
- Lead developer
- Vrije Universiteit Brussel
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
99mTc-anti-DPP6 nanobody is an experimental, preclinical radiolabeled single-domain camelid antibody (nanobody) fragment designed for non-invasive imaging of pancreatic beta-cell mass. Developed by the Vrije Universiteit Brussel (VUB) and the Université Libre de Bruxelles (ULB), the imaging agent consists of the high-affinity anti-DPP6 nanobody clone 4hD29 labeled with the radioactive isotope technetium-99m (99mTc) for single-photon emission computed tomography (SPECT) imaging. It specifically targets dipeptidyl peptidase 6 (DPP6), a cell-surface biomarker highly expressed in human pancreatic islets (specifically beta and alpha cells) and endocrine cells, as well as certain neuroblastomas. The tracer is intended as a diagnostic tool to non-invasively quantify beta-cell mass, monitor the progression of type 1 diabetes, and track the viability of transplanted pancreatic islet grafts.
- Other names
- 99mTc-labelled 4hD29 nanobodyanti-DPP6 nanobodyanti-DPP-6 nanobodyanti-DPP 6 nanobodytechnetium-99m-labelled anti-DPP6 nanobodytechnetium99m-labelled anti-DPP6 nanobodytechnetium 99m-labelled anti-DPP6 nanobody
02
Targets
DPP6 (Dipeptidyl peptidase 6)
Beyond the preview
Go deeper on 99mTc-anti-DPP6 nanobody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 99mTc-anti-DPP6 nanobody.